Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs
Abstract
Aim: Data from 69 well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy + somatostatin analogs (SSAs) after SSA treatment failure were evaluated. Methods: We identified two groups: S1 - patients who kept the same SSA treatment beyond progression; S2 - patients who switched the SSA with another SSA after progression. Results: Median progression-free survival was 53 and 127 months in...
Paper Details
Title
Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs
Published Date
Sep 1, 2019
Journal
Volume
15
Issue
26
Pages
3015 - 3024
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History